- Home
- CLMT vs NVCR Comparison
CLMT vs NVCR Comparison
Compare CLMT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLMT | NVCR |
|---|---|---|
| Founded | 1916 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2006 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CLMT | NVCR |
|---|---|---|
| Price | $19.68 | $13.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $20.45 | ★ $28.42 |
| AVG Volume (30 Days) | 580.8K | ★ 1.8M |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,048,000,000.00 | $642,269,000.00 |
| Revenue This Year | $0.23 | $9.75 |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $7.68 | $10.70 |
| 52 Week High | $23.75 | $32.06 |
Technical Indicators
Market Signals| Indicator | CLMT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 59.44 |
| Support Level | $19.19 | $12.30 |
| Resistance Level | $20.59 | $13.97 |
| Average True Range (ATR) | 0.59 | 0.55 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 29.86 | 77.21 |
Price Performance
Historical ComparisonAbout CLMT Calumet Specialty Products Partners L.P.
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.